Trial Profile
A head-to Head Comparison of the Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Pharmacodynamics
- 01 Oct 2022 Results published in the Journal of Thrombosis and Thrombolysis
- 03 Feb 2016 Results published in the European Heart Journal
- 07 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.